Relapsed/Refractory HER2+ Metastatic Breast Cancer
This article reviews the recent development of HER2-targeted therapies with central nervous system (CNS) activity that may improve survival of patients with CNS metastases and prevent development of new CNS metastases. This article also features insights from oncology experts Adam M. Brufsky, MD, PhD; V. K. Gadi, MD, PhD; Sara A. Hurvitz, MD; and Neil M. Iyengar, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Did ASCO 2026 Deliver on Its Biggest Pre-Meeting Predictions?
2
26 A Nomogram for Predicting High Axillary Disease Burden in Patients With Localized HR+, HER2-Negative Breast Cancer Following Neoadjuvant Chemotherapy
3
Why CELMoDs Pair Synergistically With PIs and CD38 Antibodies in Multiple Myeloma
4
27 Transfusion and Anemia Management Strategies in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Literature Review
5